- Home
- KFFB vs INAB Comparison
KFFB vs INAB Comparison
Compare KFFB & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFFB
- INAB
- Stock Information
- Founded
- KFFB 2005
- INAB 2016
- Country
- KFFB United States
- INAB United States
- Employees
- KFFB N/A
- INAB N/A
- Industry
- KFFB Savings Institutions
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- KFFB Finance
- INAB Health Care
- Exchange
- KFFB Nasdaq
- INAB Nasdaq
- Market Cap
- KFFB 24.3M
- INAB 24.0M
- IPO Year
- KFFB 2005
- INAB 2021
- Fundamental
- Price
- KFFB $3.04
- INAB $0.30
- Analyst Decision
- KFFB
- INAB Strong Buy
- Analyst Count
- KFFB 0
- INAB 3
- Target Price
- KFFB N/A
- INAB $7.75
- AVG Volume (30 Days)
- KFFB 4.6K
- INAB 888.1K
- Earning Date
- KFFB 02-10-2025
- INAB 03-13-2025
- Dividend Yield
- KFFB N/A
- INAB N/A
- EPS Growth
- KFFB N/A
- INAB N/A
- EPS
- KFFB N/A
- INAB N/A
- Revenue
- KFFB $7,475,000.00
- INAB N/A
- Revenue This Year
- KFFB N/A
- INAB N/A
- Revenue Next Year
- KFFB N/A
- INAB N/A
- P/E Ratio
- KFFB N/A
- INAB N/A
- Revenue Growth
- KFFB N/A
- INAB N/A
- 52 Week Low
- KFFB $2.50
- INAB $0.22
- 52 Week High
- KFFB $4.15
- INAB $1.74
- Technical
- Relative Strength Index (RSI)
- KFFB 59.37
- INAB 49.39
- Support Level
- KFFB $2.88
- INAB $0.28
- Resistance Level
- KFFB $3.05
- INAB $0.33
- Average True Range (ATR)
- KFFB 0.07
- INAB 0.04
- MACD
- KFFB 0.00
- INAB 0.00
- Stochastic Oscillator
- KFFB 57.32
- INAB 38.33
About KFFB Kentucky First Federal Bancorp
Kentucky First Federal Bancorp is a holding company. The company through its subsidiaries is engaged mainly in the business of accepting deposits from the general public and using such funds to originate loans secured by first mortgages on owner-occupied, residential real estate and other loans secured by real estate. Its primary products and services include Residential mortgage loans, Multi-family loans, Construction loans and types of deposits, etc. The company mainly operates in Perry, Franklin, Boyle and Garrard and surrounding counties in Kentucky, US.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.